Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares RepurchasedShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kewaunee Scientific (KEQU) Cash from Financing Activities (2016 - 2026)

Kewaunee Scientific has reported Cash from Financing Activities over the past 17 years, most recently at -$14.1 million for Q1 2026.

  • Quarterly results put Cash from Financing Activities at -$14.1 million for Q1 2026, down 196.07% from a year ago — trailing twelve months through Jan 2026 was -$20.7 million (down 301.5% YoY), and the annual figure for FY2025 was $7.4 million, up 345.89%.
  • Cash from Financing Activities for Q1 2026 was -$14.1 million at Kewaunee Scientific, down from -$853000.0 in the prior quarter.
  • Over the last five years, Cash from Financing Activities for KEQU hit a ceiling of $14.6 million in Q1 2025 and a floor of -$14.1 million in Q1 2026.
  • Median Cash from Financing Activities over the past 5 years was -$853000.0 (2025), compared with a mean of $419176.5.
  • Biggest five-year swings in Cash from Financing Activities: surged 639.31% in 2023 and later crashed 526.53% in 2025.
  • Kewaunee Scientific's Cash from Financing Activities stood at -$145000.0 in 2022, then surged by 639.31% to $782000.0 in 2023, then plummeted by 512.92% to -$3.2 million in 2024, then soared by 73.58% to -$853000.0 in 2025, then plummeted by 1548.3% to -$14.1 million in 2026.
  • The last three reported values for Cash from Financing Activities were -$14.1 million (Q1 2026), -$853000.0 (Q4 2025), and -$1.5 million (Q3 2025) per Business Quant data.